Anders Bach

Anders Bach


Aktuel forskning

In the Bach Group, we develop biological active small-molecule inhibitors of protein-protein interactions involved in oxidative stress and which play key roles in inflammation and brain diseases (e.g. neurodegeneration and brain cancer). We evaluate the ‘druggability’ of selected targets, and aim at developing new high-quality chemical probes useful for pharmacological studies and for identifying new therapeutic principles against diseases.

Fragment-based drug discovery (FBDD) is a core theme of our research. We screen our library of fragments (i.e. small substructures of druglike molecules) using very sensitive biophysical methods, such as SPR and NMR. Promising and validated hits are optimized into lead molecules by medicinal chemistry, biostructural studies and pharmacology.

For more information about our research and open positions, please contact

ID: 1304261